Drug Trial Radar · NCT05438407
Pediatric Patients Aged 4 to 11 Years With APDS
Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Feb 1, 2023
Primary completion
Nov 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Pharming Technologies B.V.Industry
- Sponsor type
- Industry
- Collaborators
- CMIC Co, Ltd. Japan; Labcorp Central Laboratory; Fortrea; Aixial Group
- First posted
- Jun 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of leniolisib in at least 15 pediatric patients (aged 4 to 11 years) with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).
Conditions
- APDS
Interventions
LeniolisibDrug
The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part I & II: Number of Participants with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs) , and Adverse Events (AEs)Time frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year, plus 30 days
- Part I & II: Change from baseline in clinical laboratory test resultsTime frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year
- Part I & II: Change from baseline in vital signsTime frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year
- Part I & II: Change from baseline in physical examination findingsTime frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year
- Part I & II: Change from baseline in electrocardiograms (ECGs)Time frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year, plus 30 Days
- Part I & II: Change from baseline in growth and physical developmentTime frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year
- Part I & II: Reduction in lymphoproliferation as measured by MRI or low-dose CTTime frame: Part I: Baseline and Day 85 Part II: at Day 252, through study completion, an average of 1 year
- Part I: A Percentage of Inhibition of Unstimulated and Stimulated pAkt Levels in B CellsTime frame: Part I: Baseline, Days 29, 57 and 85
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
Stanford University
Standford, California
Children's Healthcare of Atlanta
Atlanta, Georgia
National Institutes of Health
Bethesda, Maryland
Necker Hospital Paris
Paris, France
Kyoto University Hospital
Kyoto, Japan
Institute of Science Tokyo Hospital
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.